Uncategorized
Boehringer Ingelheim and Ochre Bio Join Forces in a $1 Billion Collaboration to Combat Chronic Liver Diseases
Boehringer Ingelheim, Ochre Bio, collaboration, chronic liver diseases, $1 billion, drug discovery, RNA therapeutics, liver fibrosis, non-alcoholic steatohepatitis (NASH)
BMS Expands CAR-T Therapy Capabilities with Strategic $380 Million Investment in Cellares
BMS, Bristol Myers Squibb, Cellares, CAR-T therapy, cell therapy, cancer treatment, biotechnology, investment, capacity expansion, manufacturing, automation.
Ipsen and Skyhawk Therapeutics Join Forces in a $1.8 Billion Deal to Advance RNA Modulator Research
Ipsen, Skyhawk Therapeutics, RNA modulators, drug discovery, partnership, $1.8 billion, biopharmaceutical, R&D, therapeutic development
AbbVie Emerges as Leading Immunology Company in Doctor Rankings, Surpassing Pfizer and Johnson & Johnson
AbbVie, Pfizer, Johnson & Johnson, doctor ranking, immunology companies, pharmaceutical industry, market performance, reputation, product portfolio.
CSL Vifor’s Corrective Marketing Initiative to Address Anti-Competitive Concerns
CSL Vifor, marketing campaign, anti-competitive practices, competition law, corrective measures, pharmaceutical industry, competition watchdog, market fairness.
Eli Lilly Anticipates Zepbound Label Expansion Following Positive Phase III Sleep Apnea Study Results
Eli Lilly, Zepbound (tirzepatide), Phase III Sleep Apnea Study, SURMOUNT-OSA, Obstructive Sleep Apnea (OSA), Label Expansion, Fast Track Designation, Symptom Improvement
Barinthus Bio’s HPV Immunotherapy Fails to Demonstrate Statistically Significant Efficacy in Early Study
Barinthus Bio, HPV immunotherapy, VTP-200, early study, underwhelming results, efficacy
FDA Approves Takeda’s Subcutaneous Entyvio Injection for Maintenance Therapy in Moderate to Severe Crohn’s Disease
FDA, Takeda, Entyvio, Subcutaneous, Injection, Maintenance Therapy, Crohn’s Disease
CSL Vifor Proposes Corrective Campaign to Resolve EU Antitrust Probe
CSL Vifor, EU Antitrust Probe, Corrective Campaign, Multi-Channel Communication, Competition
Roche’s Alecensa Gains FDA Approval for Postsurgical Early Lung Cancer Treatment
Roche, Alecensa, FDA approval, Postsurgical treatment, Early lung cancer